Tickers

1. Composite Trajectory Verdict

The income statement matters most for assessing FSK because as a BDC its ability to generate net investment income directly determines distribution coverage and RIC qualification, while portfolio fair value changes affect NAV but are secondary to recurring income generation.

Composite Trajectory: Deteriorating

The earnings trajectory is deteriorating: net investment income fell 19.6% YoY to $654M ($2.34/share) from $813M ($2.90/share), driven by an 11.7% decline in total investment income to $1,519M from $1,721M and a drop in weighted average yield on accruing debt to 10.1% from 11.3% (10-K FY2025, MD&A Results of Operations). The balance sheet trajectory is also deteriorating: portfolio fair value declined 3.6% to $13,009M from $13,490M, non-accrual loans rose to 3.4% from 2.2%, and combined Rating 3/4 exposures increased to 8% from 5% (10-K FY2025, MD&A Portfolio Investment Activity). Cash flow trajectory cannot be assessed due to missing statements. The only offsetting factor is a modest improvement in net realized losses (from -$476M to -$376M), but this is outweighed by a $496M negative swing in unrealized appreciation (from +$248M to -$248M) and a collapse in net increase in net assets from operations to $11M from $585M (10-K FY2025, MD&A Results of Operations).

2. Red Flags

• Net investment income per share ($2.34) fell 19.3% YoY while regular distributions per share only declined 3.4% (to $2.80 from $2.90), pressuring distribution coverage (10-K FY2025, MD&A Results of Operations; 10-K FY2025, MD&A RIC Status and Distributions).
• Unrealized appreciation swung from a $248M gain to a $248M loss, a $496M negative reversal, driven by markdowns in Production Resources Group, 48Forty Solutions, and Kellermeyer Bergensons Services (10-K FY2025, MD&A Net Change in Unrealized Appreciation).
• Non-accrual loans increased to 3.4% of portfolio fair value from 2.2% (10-K FY2025, MD&A Portfolio Investment Activity).
• Weighted average yield on accruing debt investments dropped 120 basis points to 10.1% from 11.3% (10-K FY2025, MD&A Portfolio Investment Activity).
• Combined Rating 3 and 4 investments (underperforming) rose to 8% of portfolio fair value from 5% (10-K FY2025, MD&A Portfolio Asset Quality).
• Total return on NAV nearly stalled at 0.21% versus 8.50% a year earlier; market-value total return plunged to -20.31% from +25.29% (10-K FY2025, MD&A Portfolio Investment Activity).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Total investment income decreased 11.7% YoY to $1,519M from $1,721M, with interest income down 21.8% to $917M from $1,172M and fee income down 42.9% to $36M from $63M; only PIK interest (+6.2% to $224M) and dividend income (+24.4% to $342M) rose (10-K FY2025, MD&A Revenues). Total operating expenses declined modestly to $843M from $885M, mainly from lower incentive fees ($136M vs $167M) and management fees ($206M vs $216M) (10-K FY2025, MD&A Expenses). Net investment income consequently fell 19.6% to $654M ($2.34/share) from $813M ($2.90/share) (10-K FY2025, MD&A Net Investment Income). Net realized losses improved to -$376M from -$476M, but unrealized appreciation swung to a -$248M loss from a +$248M gain, resulting in a net increase in net assets from operations of only $11M ($0.04/share) versus $585M ($2.09/share) (10-K FY2025, MD&A Net Realized Gains or Losses; Net Change in Unrealized Appreciation; Net Increase in Net Assets).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Insufficient Data

The provided filings do not include a statement of cash flows for either FY2025 or FY2024, nor do the quarterly 10-Qs contain cash flow data in the excerpts supplied. Without operating, investing, and financing cash flow figures, no trajectory can be determined.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Portfolio fair value declined 3.6% to $13,009M from $13,490M (10-K FY2025, Consolidated Balance Sheets / MD&A Portfolio Investment Activity). Credit quality weakened: non-accrual investments rose to 3.4% of fair value from 2.2%, and the share of Rating 3/4 (underperforming) assets increased to 8% from 5% (10-K FY2025, MD&A Portfolio Asset Quality). Asset coverage stood at 177% at year-end 2025, above the 150% regulatory minimum, but the prior-year coverage ratio is not disclosed in the provided material (10-K FY2025, MD&A Asset Coverage). Total debt outstanding was $7,620M at December 31, 2025; the 2024 debt figure is not provided, preventing leverage trend analysis (10-K FY2025, MD&A Financing Arrangements). Cash and available borrowings totaled $208M and $3,268M respectively, against unfunded commitments of $1,447M (debt), $88M (equity), and $245M (COPJV) (10-K FY2025, MD&A Financial Condition, Liquidity and Capital Resources).

6. Data Gaps

• Statement of cash flows for FY2025 and FY2024 (operating, investing, financing activities).
• Quarterly cash flow statements for Q2 2025, Q3 2025, Q1 2026, Q2 2026 to assess intra-year trends.
• FY2024 total debt outstanding, net asset value, and asset coverage ratio for YoY balance sheet comparison.
• Share count for FY2025 and FY2024 to verify per-share calculations independently.
• Detailed breakdown of cash vs. non-cash components of investment income (PIK, accretion) and their cash conversion timing.
• FY2024 unfunded commitment amounts for comparison with FY2025's $1,447M debt, $88M equity, $245M COPJV.